Elevidys is the first gene therapy approved for the treatment of certain patients with Duchenne muscular dystrophy (DMD)

The U.S. Food and Drug Administration (FDA) has approved Sarepta’s Elevidys (delandistrogene moxeparvovec) for the treatment of ambulant pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.¹ DMD occurs in approximately one in every 3,500 to 5,000 newborn males worldwide or about 400 to 600 boys per year in the U.S.